Glow Lifetech Corp. provided an update on commercial operations, cannabis-related development activities and clinical studies related to its proprietary MyCell®-enhanced products. Glow is now focused on the final stages of development of proprietary CBD (cannabidiol) and THC1 (tetrahydrocannabinol) water-soluble ingredients in preparation for launch in Canada.

With Glow's licensed cannabis processing space now built out and equipment successfully commissioned earlier this year, the company has been actively developing a diverse portfolio of high-bioavailability cannabis ingredients and new proprietary technologies to expand the Company's portfolio of solutions. The Company's MyCell® Technology is an advanced delivery system that transforms poorly absorbed cannabinoids, like CBD and THC, into water-soluble concentrates that have fast-acting onset, high- absorption and precise dosing. Glow is engaged with a renowned branding firm and is in the late stages of establishing a refreshed brand identity that reflects the cutting-edge performance and quality of its technology and products.

The Company is also pleased to report the completion of the recruitment phase of the ongoing clinical study on patients with long COVID syndrome, to assess the impact of its proprietary natural health product Artemic Support®, which features MyCell® Technology.2 Glow's portfolio of high-performance water-soluble cannabis ingredient solutions will unlock a step- change in what's possible with cannabis-infused products, enabling partner brands to easily innovate and differentiate with high-value products that are more effective, fast-acting, consistent and deliver predictable dosing. The versatility of MyCell® enhanced concentrates allows them to power a variety of product formats including: droppers, beverages, foods, topicals, and capsules.